From Pac-Man to powerhouseHealthcare is a huge cost for Canadian governments, but it could become a major driver of economic growth. Globally, Canada is uniquely positioned to realize that potential Nurse-based model of care effective for chronic kidney diseaseStudy finds model decreases costs without reducing quality of life. Monoclonal antibody an add-on for lupus treatment Drug News: September 2011 Benlysta: new IV immunosuppressant for SLE; Brilinta: new antiplatelet agent for prevention of CV events after ACS. Xgeva reduces risk of skeletal events in cancer patients with bone metastases Drug indicated for reducing the of developing skeletal-related events in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer and other solid tumours. Men and Women's Health 2010: Osteoporosis New developments in therapy, vitamin D requirements, bisphosphonate safety and risk assessment. Drug News: October 2010 Dexilant: new PPI, lansoprazole enantiomer; Prolia: twice-yearly SC injection for osteoporosis; Thalidomide approved for multiple myeloma. Thalidomide returns – with a catch Prolia: twice-yearly SC injection for osteoporosis Anemia common – but missed – after kidney transplantation Canadian study shows hypercalcemia also occurs frequently First Previous 6 7 8 9 Next Last
